Infinity BiologiX, LLC (IBX).
The Accreditation Committee of the College of American Pathologists (CAP) awarded accreditation to IBX, Piscataway, New Jersey Laboratory, based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs.
Chief Scientific Officer, Shareef Nahas, PHD, was advised of this national recognition and congratulated for the excellence of the services being provided. IBX is one of more than 8,000 CAP-accredited facilities worldwide.
“With CAP inspections every three years, renewing this accreditation is always an important milestone for IBX and we’re incredibly proud to receive this news. It represents the ongoing efforts of our team and how well placed we are to support our clients with the breadth of experience we have in biobanking and the management of biospecimens,” said Nahas.
Robin Grimwood, CEO at IBX, said: “Maintaining high quality and standards as we more than double the size of our biorepository is essential for our clients and their samples. We know biospecimens are integral to improving patient outcomes and demand for biobanking services to support precision medicine is greater than ever. At IBX we see the standards set by CAP, which draws on best practices from ISBER, NCI, OECD, CMS, as vital to our mission to be the lab behind every transformative health innovation.”
About the College of American Pathologists: As the world’s largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, the College of American Pathologists (CAP) serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, read the CAP Annual Report at cap.org.
About Infinity BiologiX (IBX): IBX is a market-disrupting next-generation central laboratory supporting academia, government, and industry. IBX provides global sample collection, processing, storage, and analytical services integrated with scientific and technical support in both the research and clinical arenas. As a leader in biomaterials, IBX provides support to the development of diagnostics, therapeutics, and research in the genomics, precision, and regenerative medicine arenas. IBX previously operated as RUCDR Infinite Biologics before spinning off from Rutgers University-New Brunswick in August 2020.
For more information, please visit www.ibx.bio.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211222005395/en/
Contacts
Media: Mike Thurogood Mike.thurogood@infinity-biologix.com
